

12th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice and Post-MASCC

Organizing Committee

Institut Jules Bordet:

A. Awada, N. Kotecki, P. Aftimos, M. Piccart-Gebhart

BSMO:

J. De Grève, P. Vuylsteke, L. Dirix

Post-MASCC:

J. Klastersky, C. Fontaine

23 - 24 November 2018
Parker Hotel Brussels,
Bessenveldstraat 15,
Diegem, Belgium

Post-MASCC

Friday 23rd November 2018 Morning

9.00 – 9.05	Introduction – J. Klastersky & C. Fontaine
9.05 – 9.35	Fertility, sexuality and cancer – M. Lambertini (IJB)
9.35 – 10.05	Multicultural approaches of pain – P. Crombez (IJB)
10.05 – 10.35	Cannabinoids: a new approach for pain control? – D. Lossignol (IJB)
10.35 – 10.50	Coffee Break
10.50 – 11.20	Management of side effects of immunotherapy and targeted therapies – F. Scotté (Paris)
11.20 – 11.50	Cachexia – J. M. Argiles (Barcelona)
11.50 – 12.20	Photobiomodulation for mucositis and radiodermatitis – Mebis and Robijns (Hasselt)
12.20 – 12.30	Conclusions – J. Klastersky & C. Fontaine

Friday 23rd November 2018 Afternoon

13.30 - 14.00		Arrival – coffee and tea
14.00		Welcome – A. Awada (IJB) & J. De Grève (UZ Brussel)
14.00 – 15.00	14.00 – 14.15	Role of PDL1 expression in BC stem cells : implication for novel therapeutic approaches – M. Di Nicola (Milan)
<u>Chair :</u> Dr Awada	14.15 – 14.30	Clinical implications of somatic mutations in solid tumors – J. De Grève (UZ Brussel)
	14.30 – 14.45	Advancing precision medicine : the role of data sharing – P. Aftimos (IJB)
	14.45 – 15.00	Discussion
15.00 - 15.40		Escalation/de-escalation therapeutic strategy in the early settings :
<u>Chair :</u> Dr Vuylsteke	15.00 – 15.20	• The example of breast cancer – H. Wildiers (UZ Leuven)
	15.20 – 15.40	• The example of head & neck cancer – P. Specenier (UZA) TBC
15.40 - 16.00		Coffee Break
16.00 – 17.15	16.00 – 16.20	Checkpoints inhibitors (CPIs) in the early setting of solid cancers : promising findings and perspectives – N. Kotecki (IJB)
<u>Chair :</u> Dr Aspeslagh	16.20 – 16.40	PD-L1, mutational burden and other biomarkers of CPIs : where are we ? – P. Pauwels (UZA)
	16.40 – 16.55	Patients-reported outcomes and CPIs : how, when and clinical implications – S. Aspeslagh (IJB) TBC
	16.55 – 17.15	Discussion
17.15 – 18.05	17.15 – 17.35	Prostate cancer from PSA elevation to late stage : therapeutic algorithm – D. Mukherji (American University of Beirut)
<u>Chair :</u> Dr Gil	17.35 – 17.50	Sarcomas – Jungels (IJB)
	17.50 – 18.05	Ovarian cancer : therapeutic news – J. Kerger (IJB)

Saturday 24th November 2018 Morning

8.00 - 8.30		Arrival – coffee and tea
8.30 - 9.30 Chair : Dr Awada	8.30 – 8.45	Liquid biopsy : ready for clinical practice ? – M. Ignatiadis (IJB)
	8.45 – 9.00	Clinical challenges of checkpoints inhibitors (CPIs) in solid tumors – V. Kruse (UZ Gent) TBC
	9.00 – 9.15	Tumor agnostic-directed therapy : benefits, limitations and perspectives – L. Dirix (Iridium)
	9.15 – 9.30	CAR-T and solid cancers : hope or hype ? – S. Rottey (UZ Gent)
9.30 - 10.30 Chair : Dr Van Laethem	Data changing practice in solid tumors :	
	9.30 – 10.00	Non-colorectal cancer – P. Papanastasopoulos (Cyprus Oncology centre)
	10.00 – 10.15	Colorectal cancer – J. Collignon (CHU Liège)
	10.15 – 10.30	Molecularly-defined melanoma : implications for clinical practice – O. Bechter (KUL)
10.30 – 11.00		Coffee Break
11.00 – 11.45 Chair : Dr Holbrechts	11.00 – 11.15	Urothelial tumors – Ph. Barthélémy (CHRU Strasbourg)
	11.15 – 11.30	Renal cell carcinoma – E. Seront (St Luc)
	11.30 – 11.45	Thoracic tumors – G. Berchem (CHL)
11.45 – 12.00		Pfizer Oncology Award - S. Rottey (UZ Gent)
12.00 - 12.30 Chair : Dr Canon		Update on breast cancer systemic therapy for clinical practice – A. Awada (IJB)
12.30		Conclusions